IL-27 rs153109 Polymorphisms and serum level as prognostic risk factor to relapse and resistance in adult patients with Acute Lymphoblastic Leukemia

Abstract

Author(s): Zainab Kadhim Abdul-Hussein, Prof. Ibrahim A. Al-Tamemi

Background: Acute Lymphoblastic Leukemia (ALL) is a malignant transformation and proliferation of lymphoid progenitor B cell (BCP- ALL) or T cell (T-ALL) origin that invade the bone marrow, blood and extramedullary sites. While many studies addressed the outcome of adult ALL in developed Western countries, there is paucity of such prospective studies from developing Mediterranean ones. This study conducted at Baghdad Teaching Hospital/ Hematology center in Iraq to detect Interleukin (IL)-27 polymorphism and serum level because this cytokine has important anti-cancer activity. Aim: our aim of the present study is to investigate the possible role of IL27 gene polymorphism as risk factors for the development and whether they effect on the clinical outcome of ALL in Iraqi adult patients , along with possibilities for using IL27 amount in blood for monitoring relapse and resistant patients Materials and Methods: A case control study have been conducted and based on : 70 adult Iraqi patients diagnosed clinically by physician as having ALL and 40 healthy control to genotyping of IL27 (rs153109) single nucleotide polymorphisms (SNPs) which was accomplished using a polymerase chain reaction–restriction fragment length polymorphism (RFLP-PCR) assay and ELISA for measure serum level IL27 . Results: Comparison of frequencies of IL-27-AG genotypes and alleles between control group and group of response show Genotypes AA and A/G were not significantly associated with response group , but alleles showed significant variation in such a way that allele A was against response and allele G was with response , Comparison of IL-27 AG genotypes and allele frequencies between group of response and group of no response there was no significant difference in genotypes or allele frequencies thus, no genotypes or allele can be regarded as a risk or a protective factor. Regarding IL-27 level in serum, there was significant difference among groups (p<0.001) in such a way the levels in relapse and resistance groups higher than both control group and response group (p<0.05 ). Conclusion: IL27 is good biomarker for prognosis relapse in patient that complete treatment and therapy resist and must continuously doing checkup , also open agate for using them as new therapeutic target

Share this article